Abstract: A compound of formula (I), for use in the treatment of non-traumatic acquired brain injury, in which M represents a NR1R2 group, an OR1 group or a SR1 group, A represents a NR4R5 group, an OR10 group or a hydrogen atom, R3 is a (C1-C6)alkyl group, a (C1-C6)cycloalkyl group, an aryl group, a —CH2-aryl group, a CH2-(C1-C6)cycloalkyl group or a —CH2-heteroaryl group, and its addition salts with pharmaceutically acceptable acids. A compound of formula (I) wherein R5 is a (C1-C8)alkyl group or a (C1-C6)cycloalkyl group, said alkyl and cycloalkyl group being substituted with one, two or three —OCORa group(s).
Type:
Application
Filed:
April 23, 2021
Publication date:
June 15, 2023
Applicants:
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, WOMEN & INFANTS HOSPITAL OF RHODE ISLAND, SCIENTIAM PHARMA